A revolving door between Verily and the FDA; figuring out why CAR-T doesn't always work

Alphabet spinout Verily is building technology to bolster the use of real-world evidence. It is making notable hires from the FDA to do so. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by       STAT+: At Verily, a growing line of business builds on a revolving door to the FDA By Katie Palmer Sipa via AP Alphabet spinout Verily is building technology to bolster the use of real-world evidence. It is making notable hires from the FDA to do so. Read More STAT+: CAR-T therapy doesn't work in all cancer cases. Scientists are starting to figure out why By Angus Chen Adobe Two teams of scientists identify a possible saboteur in the mix of immune cells that were engineered to help. Read More 'History is repeating itself': The story of the nation's first clinic for gender-affirming surgery By Theresa Gaffney Nicolas AsfouriAFP/Getty Images Nearly 60 years ago, Johns Hopkins Hospital opened a first-of-its-kind clinic to provide gender-affirming surgery. Read More Sponsor content by STAT TRIALS PULSE What if you had clinical trials news 51 days early? Earlier this year, STAT Trials Pulse detected roadblocks for TG Therapeutics’s Umbralisib 51 days before the company pulled it from the market. Read our latest case study to see how you can get market-moving news like this, ahead of everyone else. Opinion: Messaging — the unrecognized coefficient in pandemic control — matters By Jim Downs and Eleanor J. Murray Federal Art Project/Library of Congress Public health messaging helped stop the 1920s diphtheria epidemic in New York. It can do the same for the Covid-19 pandemic today. Read More Tuesday, October 4, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser